New insights in the field of muscle glycogenoses

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 544-553

  Oldfors, Anders ^a   Dimauro, Salvatore ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE PHOSPHATE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE 1 PHOSPHATE; GLUCOSE 6 PHOSPHATE; GLYCERIC ACID; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; LACTATE DEHYDROGENASE; PHOSPHOENOLPYRUVATE; PHOSPHOGLUCOMUTASE; PHOSPHOGLYCERATE MUTASE; PHOSPHORYLASE KINASE; PYRUVIC ACID; RBCK1 PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE;

CARDIOMYOPATHY; ENZYME REPLACEMENT; ERGOMETRY; EXERCISE; GLUCOSE INFUSION; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 4; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HETEROZYGOTE; HUMAN; MUSCLE CRAMP; MUSCLE WEAKNESS; MYOGLOBINURIA; MYOPATHY; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; EXERCISE; GLYCOGEN STORAGE DISEASE; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 84883779354     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364dbdc     Document Type: Review

References (46)

1. Stojkovic T, Vissing J, Petit F, et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med 2009; 361:425-427.
2. Preisler N, Laforet P, Echaniz-Laguna A, et al. Fat and carbohydrate metabolism during exercise in phosphoglucomutase type 1 deficiency. J Clin Endocr Metab 2013; 98:E1235-E1240.
3. Perez B, Medrano C, Ecay MJ, et al. A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene. J Inher Metab Dis 2013; 36:535-542.
4. Nogales-Gadea G, Pinos T, Lucia A, et al. Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease. Brain 2012; 135:2048-2057.
5. Birch KE, Quinlivan R, Morris GE. Cell model for McArdle disease and aminoglycoside-induced read-through of a premature termination codon. Neuromusc Dis 2013; 23:43-51.
6. Sato S, Ohi T, Nishino I, Sugie H. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve 2012; 45:436-440.
7. Musumeci O, Bruno C, Mongini T, et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD VII). Neuromusc Dis 2012; 22:325-330.
8. Dunaway GA, Kasten TP, Sebo T, Trapp R. Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem J 1988; 251: 677-683.
9. Salameh J, Goyal N, Choudry R, et al. Phosphoglycerate mutase deficiency with tubular aggregates in a patient from Panama. Muscle Nerve 2013; 47:138-140.
10. Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 2007; 357:1507-1514.
11. Moslemi A-R, Lindberg C, Nilsson J, et al. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N Engl J Med 2010; 362: 1203-1210.
12. Cameron JM, Levandovskiy V, MacKay N, et al. Identification of a novel mutation in GSY1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. Mol Genet Metab 2009; 98:378-382.
13. Sukigara S, Liang W-C, Komaki H, et al. Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia. Neuromusc Dis 2012; 22:162-165.
14. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68:99-109.
15. van der Ploeg AT, Reuser A. Pompe's disease. Lancet 2008; 372:1342-1353.
16. Raben N, Wong A, Ralston E, Myerowitz R. Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgotten. Am J Med Genet 2012; 160C:13-21.
17. Kishnani P, Beckemeyer AA, Mendelsohn NJ. The new era of Pompe disease: Advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet 2012; 160C:1-7.
18. Spiridigliozzi GA, Heller JH, Kishnani PS. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: Long-term follow-up. Am J Med Genet 2012; 160C: 22-29.
19. Ebbink RJ, Aarsen FK, van Gelder CM, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 2012; 78:1512-1518.
20. van Gelder CM, van Capelle CI, Ebbink RJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inher Metab Dis 2012; 35:505-511.
21. Kroos M, Hoogeveen-Westerveld M, Van der Ploeg A, Reuser AJJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet 2012; 160C:59-68.
22. Remiche G, Herbaut A-G, Ronchi D, et al. Incontinence in late-onset Pompe disease: An underdiagnosed treatable condition. Eur Neurol 2012; 68:75-78.
23. Hobson-Webb LD, Proia AD, Thurberg BL, et al. Autopsy findings in lateonset Pompe disease: A case report and systematic review of the literature. Mol Genet Metab 2012; 106:462-469.
24. Musumeci O, Catalano N, Barca E, et al. Auditory system involvement in late onset Pompe disease. A study of 20 Italian patients. Mol Genet Metab 2012; 107:480-484.
25. van der Beck NAME, Verschuure H, Reuser A, et al. Hearing in adults with Pompe disease. J Inher Metab Dis 2012; 35:335-341.
26. Preisler N, Laforet P, Lindhardt Madsen K, et al. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. Mol Genet Metab 2012; 107:462-468.
27. Regnery C, Kornblum C, Hanisch F, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inher Metab Dis 2012; 35:837-845.
28. Furusawa Y, Mori-Yoshimura M, Yamamoto T, et al. Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: A 2-year follow-up. J Inher Metab Dis 2012; 35:301-310.
29. Ravaglia S, De Filippi P, Pichiecchio A, et al. Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset type II glycogenosis?. Mol Genet Metab 2012; 107:104-110.
30. Li S, Sun B, Nilsson ML, et al. Adjunctive beta-2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J 2013; 27:34-44.
31. DiMauro S, Hartwig GB, Hays AP, et al. Debrancher deficiency: Neuromuscular disorder in five adults. Ann Neurol 1979; 5:422-436.
32. DiMauro S, Spiegel R. Progress and problems in muscle glycogenoses. Acta Myologica 2011; 30:96-102.
33. Preisler N, Pradel A, Husu E, et al. Exercise intolerance in glycogen storage disease type III: Weakness or energy deficiency?. Mol Genet Metab 2013; 109:14-20.
34. Ravenscroft G, Thompson EM, Todd EJ, et al. Whole exome sequencing in foetal akinesia expands the genotype-phenotype spectrum of GBE1 glycogen storage disease mutations. Neuromusc Dis 2013; 23:165-169.
35. Li S-C, Hwu W-L, Lin J-L, et al. Association of the congenital neuromuscular form of glycogen storage disease type IV with a large deletion and recurrent frameshift mutation. J Child Neurol 2012; 27:204-208.
36. Billot S, Herve D, Akman HO, et al. Acute but transient neurological deterioration revealing adult polyglucosan body disease. J Neurol Sci 2013; 324:179-182.
37. Akman HO, Sheiko T, Tay SKH, et al. Generation of a novel mouse model that recapitulates early and adult onset glycogenosis type IV. Hum Mol Genet 2011; 20:4430-4439.
38. Delgado-Escueta AV. Lafora progressive myoclonus epilepsy. Glycogen storage disease vs neurodegenerative disease. Neurology 2012; 79:21-22.
39. Tiberia E, Turnbull J, Wang TJ, et al. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. J Biol Chem 2012; 287:25650-25659.
40. Turnbull J, DePaoli-Roach AA, Zhao X, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet 2011; 7:e1002037.
41. Bornemann A, Besser R, Shin YS, Goebel HH. A mild adult myopathic variant of type IV glycogenosis. Neuromusc Disord 1996; 6:95-99.
42. Goebel HH, Shin YS, Gullotta F, et al. Adult polyglucosan body myopathy. J Neuropathol Exp Neurol 1992; 51:24-35.
43. Schroder JM, May R, Shin YS, et al. Juvenile hereditary polyglucosan body disease with complete branching enzyme deficiency (type IV glycogenosis). Acta Neuropathol 1993; 85:419-430.
44. Nilsson J, Schoser BGH, Laforet P, et al. Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1. Ann Neurol 2013. (in press).
45. Boisson B, Laplantine E, Prando C, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012; 13:1178-1186.
46. McCue ME, Valberg SJ, Miller MB, et al. Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis. Genomics 2008; 91:458-466.